For adult patients with CML failing
on one 2G TKI, ICLUSIG® combines
experience and data to improve
their future
1–3*
Because
Tomorrow
Matters
CML
ICLUSIG® is indicated in adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315l mutation
Blue square
Also available
for your
patients with
Ph+ ALL
Ph+ ALL
ICLUSIG® is indicated in adult patients with Philadelphia
chromosome positive acute lymphoblastic leukemia
(Ph+ ALL) who are resistant to dasatinib; who are
intolerant to dasatinib and for whom subsequent
treatment with imatinib is not clinically appropriate;
or who have the T315l mutation

All AEs should be reported to the Global Medical Information Call Center by phone: +800 000 27423
(for local numbers see www.incyteglobalmedicalinformation.com/report-adverse-event.aspx).
Alternatively, you can report AEs by email: eumedinfo@incyte.com

For more information, please contact Incyte Medical Information: eumedinfo@incyte.com